Oliver Hantschel
Oliver Hantschel
Assistant Professor, EPFL
Bestätigte E-Mail-Adresse bei epfl.ch
Zitiert von
Zitiert von
Structural basis for the autoinhibition of c-Abl tyrosine kinase
B Nagar, O Hantschel, MA Young, K Scheffzek, D Veach, W Bornmann, ...
Cell 112 (6), 859-871, 2003
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
U Rix, O Hantschel, G Dürnberger, LL Remsing Rix, M Planyavsky, ...
Blood, The Journal of the American Society of Hematology 110 (12), 4055-4063, 2007
Regulation of the c-Abl and Bcr–Abl tyrosine kinases
O Hantschel, G Superti-Furga
Nature reviews Molecular cell biology 5 (1), 33-44, 2004
A myristoyl/phosphotyrosine switch regulates c-Abl
O Hantschel, B Nagar, S Guettler, J Kretzschmar, K Dorey, J Kuriyan, ...
Cell 112 (6), 845-857, 2003
An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells
T Bürckstümmer, KL Bennett, A Preradovic, G Schütze, O Hantschel, ...
Nature methods 3 (12), 1013-1019, 2006
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
O Hantschel, U Rix, U Schmidt, T Bürckstümmer, M Kneidinger, G Schütze, ...
Proceedings of the National Academy of Sciences 104 (33), 13283-13288, 2007
The DEAD‐box helicase DDX3X is a critical component of the TANK‐binding kinase 1‐dependent innate immune response
D Soulat, T Bürckstümmer, S Westermayer, A Goncalves, A Bauch, ...
The EMBO journal 27 (15), 2135-2146, 2008
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
LLR Rix, U Rix, J Colinge, O Hantschel, KL Bennett, T Stranzl, A Müller, ...
Leukemia 23 (3), 477-485, 2009
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
O Hantschel, U Rix, G Superti-Furga
Leukemia & lymphoma 49 (4), 615-619, 2008
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase
B Nagar, O Hantschel, M Seeliger, JM Davies, WI Weis, G Superti-Furga, ...
Molecular cell 21 (6), 787-798, 2006
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation
P Filippakopoulos, M Kofler, O Hantschel, GD Gish, F Grebien, E Salah, ...
Cell 134 (5), 793-803, 2008
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia
O Hantschel, W Warsch, E Eckelhart, I Kaupe, F Grebien, KU Wagner, ...
Nature chemical biology 8 (3), 285-293, 2012
Charting the molecular network of the drug target Bcr-Abl
M Brehme, O Hantschel, J Colinge, I Kaupe, M Planyavsky, T Köcher, ...
Proceedings of the National Academy of Sciences 106 (18), 7414-7419, 2009
A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain
J Wojcik, O Hantschel, F Grebien, I Kaupe, KL Bennett, J Barkinge, ...
Nature structural & molecular biology 17 (4), 519-527, 2010
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease
AL Mahul-Mellier, B Fauvet, A Gysbers, I Dikiy, A Oueslati, S Georgeon, ...
Human molecular genetics 23 (11), 2858-2879, 2014
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis
F Grebien, O Hantschel, J Wojcik, I Kaupe, B Kovacic, AM Wyrzucki, ...
Cell 147 (2), 306-319, 2011
Structure, regulation, signaling, and targeting of abl kinases in cancer
O Hantschel
Genes & cancer 3 (5-6), 436-446, 2012
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
JA Winger, O Hantschel, G Superti-Furga, J Kuriyan
BMC structural biology 9 (1), 1-12, 2009
Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)
T Zhou, S Georgeon, R Moser, DJ Moore, A Caflisch, O Hantschel
Leukemia 28 (2), 404-407, 2014
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib
DW Sherbenou, O Hantschel, I Kaupe, S Willis, T Bumm, LP Turaga, ...
Blood, The Journal of the American Society of Hematology 116 (17), 3278-3285, 2010
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20